Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:elbasvir
gptkb:grazoprevir |
| gptkbp:approvalYear |
2016
|
| gptkbp:ATCCode |
gptkb:J05AP55
|
| gptkbp:combines |
ribavirin
|
| gptkbp:contains |
elbasvir 50 mg
grazoprevir 100 mg |
| gptkbp:contraindication |
severe hepatic impairment
|
| gptkbp:form |
gptkb:tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Zepatier
|
| gptkbp:indication |
gptkb:chronic_hepatitis_C
HCV genotype 1 HCV genotype 4 |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Merck_&_Co.
|
| gptkbp:mechanismOfAction |
inhibits HCV replication
|
| gptkbp:pregnancyCategory |
B (US)
|
| gptkbp:regulates |
approved
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
fatigue headache elevated liver enzymes |
| gptkbp:target |
gptkb:HCV_NS3/4A_protease
gptkb:HCV_NS5A_protein |
| gptkbp:bfsParent |
gptkb:MRK
|
| gptkbp:bfsLayer |
5
|